SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
- Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform;
- Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs;
- Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million;
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
- SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need.
- Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors.
- Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million.
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
- PPF Group provides funding to advance SOTIO through key clinical milestones
- Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
- Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.
SOTIO Biotech B.V.
Strawinskylaan 933
1077XX Amsterdam
Netherlands
Strawinskylaan 933
1077XX Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
Term of use
Data protection
Cookies Policy
Cookie settings
Clinical Trials Privacy Notice
© 2013 - 2024 Sotio
Sitemap
Terms of Use and Privacy
© 2013 - 2024 Sotio